Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
The goal of this study is to study NIS expression in benign and malignant breast and thyroid samples using archival formalin-fixed paraffin-embedded tissue sections.
Condition or disease
Breast CancerStomach NeoplasmsSalivary Gland NeoplasmsThyroid Cancer
The objective of the study is to further understanding of proteins that occur in both normal cells and tumor cells and to learn more about certain diseases and potential alternative treatments for these diseases.
Cases will be identified from clinic patient medical records and linked to pathology reports. The surgical pathology record number will thus be obtained and used to retrieve the archival blocks and slides. Approximately three representative blocks will be selected and 4-6 four micron thick sections will be cut on a microtome. Cases with limited archived diagnostic material will not be selected nor blocks where there is little materials.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Cases will be identified from clinic patient medical records and linked to pathology reports. The surgical pathology record number will thus be obtained and used to retrieve the archival blocks and slides. In addition, all these participants will be clinical patients of the Protocol Director, thus the Physician will always be familiar with the participants.
Patient must be over the age of 18.
Patients must have benign and malignant breast and thyroid cancer.